Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$155.04 USD
-0.43 (-0.28%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
by Zacks Equity Research
TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates
by Zacks Equity Research
Halozyme (HALO) reports mixed first-quarter 2024 earnings. The company maintains revenue guidance for 2024.
The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips
by Zacks Equity Research
Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips are included in this Analyst Blog.
Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix
by Sheraz Mian
Today's Research Daily features the Q1 earnings season scorecard and updated analyst reports on Tesla (TSLA), JNJ (JNJ), Netflix (NFLX) and others.
A Look at Pharma ETFs Post Q1 Earnings
by Sweta Killa
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
by Kinjel Shah
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
5 Stocks in Focus on Their Recent Dividend Hike
by Nalak Das
Five stocks to focus with recent dividend hike are: JNJ, TRV, SON, KBH, SPFI.
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.
The Zacks Analyst Blog Highlights KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson
by Zacks Equity Research
KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson are part of the Zacks top Analyst Blog.
4 Stocks to Watch on Their Recent Dividend Hikes
by Ritujay Ghosh
Stocks like KB Home (KBH), Interactive Brokers Group, Inc. (IBKR), QUALCOMM Incorporated (QCOM) and Johnson & Johnson (JNJ) recently hiked dividends.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
by Kinjel Shah
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
The Zacks Analyst Blog Highlights NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and Textron
by Zacks Equity Research
NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and Textron are included in this Analyst Blog.
Top Stock Reports for NVIDIA, Alphabet & Johnson & Johnson
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ).
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
by Sweta Killa
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
Company News for Apr 17, 2024
by Zacks Equity Research
Companies In The Article Are:LYV,JNJ,AMD,PNC
Building Permits Come in Lower Than Expected
by Zacks Equity Research
Building Permits Come in Lower Than Expected.